Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.
NCT04488484 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2023-04-27
Summary
The Coronavirus SARS CoV-2 (COVID-19) pandemic is causing a major global health crisis that is disrupting our hospital organizations and creating potential infectious risks for hospital staff on the front line when it comes to the support of infected people.
In this context, the Paris Saint-Joseph Hospital Group (GhPSJ) very early on wanted to implement an institutional approach aimed, on the one hand, at enabling each of its employees at its two sites (Hôpital Paris Saint-Joseph (HPSJ), Paris 14ème and Hôpital Marie Lannelongue (HML), Le Plessis Robinson, 92) to access their serological status with regard to SARS-CoV-2 and, on the other hand, to identify the risk factors for contracting COVID-19.
This collective approach consisted of an evaluation of its professional practices aimed at assessing the protective measures put in place to protect hospital personnel and identifying sources of potential improvement in the management of the infectious risk required to put in place in case of upcoming COVID-19 cases or any other epidemics in the future.
Conditions
Interventions
- OTHER
-
Serology test follow-up
The enrolled participants will be invited to visit ESS. They will then meet the occupational physician, who wil obtain their free, informed and written consent. The information and consent will be recorded in the personal medical follow-up file.The staff will then complete the self-questionnaire and the ESS physician will provide a prescription for the blood samples to be taken. In case of positive answers to one or more of the questions in this self-questionnaire, the enrolled participant will be contacted in order to schedule another post-COVID-19 consultation with additional examinations if needed (new COVID PCR, scanner, etc.).
Sponsors & Collaborators
-
Fondation Hôpital Saint-Joseph
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-07-01
- Primary Completion
- 2021-12-31
- Completion
- 2022-05-23
Countries
- France
Study Locations
More Related Trials
-
Brazilian Registry for Clinical Presentation of Individuals With COVID-19 (SARS-Brazil)
NCT04479488 ·Status: COMPLETED
-
Study of Methicillin-resistant Staphylococcus Aureus (MRSA) Isolated From Infected Patients in Brazil
NCT01359358 ·Status: UNKNOWN
-
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
NCT04885452 ·Status: COMPLETED
-
Immune Response and Risk of Serious Infection to SARS-Cov2
NCT04410432 ·Status: COMPLETED
-
Staphylococcus Aureus Nasal Carriage
NCT02796690 ·Status: COMPLETED
-
CORE Study COVID-19
NCT04531202 ·Status: UNKNOWN
-
Viral Load Analysis of the SARS-CoV-2 Virus in Nose Versus Mouth Sites
NCT05769803 ·Status: UNKNOWN ·Phase: NA
-
Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis
NCT06305468 ·Status: RECRUITING
-
French COVID Cohort
NCT04262921 ·Status: ACTIVE_NOT_RECRUITING
-
The South Proxa-Rescue AndroCoV Trial Against COVID-19
NCT05126628 ·Status: COMPLETED ·Phase: PHASE3
-
Mucormycosis in ICU
NCT03387696 ·Status: COMPLETED
-
PHAGEinLYON Clinic Cohort Study: a Descriptive Study of Severe Infections Treated With Phage Therapy at the HCL.
NCT06185920 ·Status: RECRUITING
-
Epidemiological Description of the Kaposi's Disease in France's Southeast
NCT03662828 ·Status: UNKNOWN
-
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
NCT05020145 ·Status: COMPLETED
-
Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
NCT04335383 ·Status: RECRUITING
-
Collection of Additional Biological Samples From Potentially COVID-19 Patients for Monitoring of Biological Parameters Carried Out as Part of the Routine
NCT06144333 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Antibiotics Use and Carriage of Methicillin-resistant Staphylococci in Community Patients
NCT01489878 ·Status: COMPLETED
-
Hospital Acquired and Community Acquired MRSA in GI Lab
NCT00577343 ·Status: WITHDRAWN
-
Predictors of Infective Endocarditis Among Patients Managed for Staphylococcus Aureus Bacteremia, Particularly Staphylococcus Aureus Bacteriuria, and Time to Blood Culture Positivity
NCT05522764 ·Status: UNKNOWN
-
Development and Validation of (Bio)Sensors for the Identification of Pathogens
NCT06548841 ·Status: COMPLETED
-
Multiple-Center Retrospective Study of Severe and Critical COVID-19 in Shanghai
NCT05422963 ·Status: UNKNOWN
-
Dysbiosis & Long COVID
NCT06825819 ·Status: RECRUITING
-
The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes
NCT04832932 ·Status: ACTIVE_NOT_RECRUITING
-
Post COVID-19 Biorepository
NCT04885504 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne
NCT02557568 ·Status: COMPLETED ·Phase: NA